The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer.

Related Articles

The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer.

Hematol Oncol Clin North Am. 2017 Jun;31(3):485-498

Authors: Murphy AG, Kelly RJ

Abstract
The connection between inflammation and malignancy has long been recognized in gastric and esophageal cancers. Given the considerable success of immune checkpoint inhibitors in other tumor types, for example, lung cancer and melanoma, much attention is being paid to furthering their role in gastric and esophageal cancers. The Cancer Genome Atlas has provided further details of the molecular heterogeneity of these tumors, which may help predict responsiveness to immune checkpoint inhibitors. This article discusses the rationale for investigating these agents in gastroesophageal cancer and summarizes the relevant clinical trial data and ongoing studies.

PMID: 28501089 [PubMed - in process]

http://ift.tt/2pOeCUP


http://ift.tt/2qkHG9A